Sri Kota Weighs in On the Evolving Breast Cancer Paradigm
In this episode of “The Vitals,” Sri Kota, MSN, BA, RN, OCN, reflects on nurse-specific takeaways from SABCS 2021, exciting changes in the breast cancer space, and the importance of patient education in the face of new regimens.
For this episode of The Vitals, Oncology Nursing News® spoke with Sri Kota, MSN, BA, RN, OCN, a nurse clinician with the Rutgers Cancer Institute of New Jersey, about important updates in the breast cancer treatment paradigm for nurses to consider.
The increasing availability of options for patients with metastatic disease is exciting, said Kota, with promising drugs such as fam-trastuzumab deruxtecan-nxki (Enhertu) and sacituzumab govitecan-hziy (Trodelvy) continuing to make waves in the field.
“[There] is something to look forward to,” she said. “The pipeline looks great.”
If you liked today’s episode of The Vitals, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms, to get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to The Vitals. Be sure to never miss a beat with Oncology Nursing News®.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.
